It was an honor (and very intimidating!) to share a stage with Nobel laureates and Pulitzer prize winners at this week’s hashtag#ABI24 (Accelerating Bio-Innovation) meeting at the Wellcome Genome Campus in Cambridge, UK. Market access hurdles can be a head scratcher for even the brightest scientific minds. Thank you to Royalty Pharma for inviting me to share my views! https://abiconference.com/
read full article ›Curious about prescription digital therapeutics and what's required for payer coverage. Our colleague Rob O'Brien will be in Nawlins next week for AMCP 2024. Laissez les bons temps rouler!
read full article ›Asembia24 is less than one month away. Don't gamble with your market access needs. Connect with the Real Endpoints team: Jeff Berkowitz, Susan Raiola, Rob O'Brien, Ryan Walsh, and Jeff Parish. We'll be on the ground in Las Vegas starting April 28.
read full article ›There's been much discussion about just how much impact lowering of out-of-pocket maximums, a major feature of the Part D redesign, will have on patient affordability. Data from RE Assist, our AI-based platform that identifies and validates new sources of copay and deductible foundation support, suggests that even with lower OOP maximums, patients will continue struggle to afford their meds.
read full article ›The Real Endpoints team is taking on PCMA today and tomorrow in Orlando. Would love to touch base if you are attending!
read full article ›At Real Endpoints, Rare Disease Day isn't just another awareness day—it's personal. Many of us here have been directly touched by the challenges and triumphs associated with living with a rare disease, whether through personal experience or those of friends and loved ones.
read full article ›The team at Real Endpoints has been working tirelessly to improve RE Assist, a simple, easy-to-use AI-based platform designed to solve a critical gap in the market: providing patients with real-time information about available third-party foundation dollars for prescription meds.
read full article ›As Interest Rates Begin to Drop, which Biotechs Will Get an Unfair Share of New Investment?
read full article ›Your semi-regular reminder: Healthcare. Is. Hard.
read full article ›This new Health Affairs Forefront article explains in simple language why it's past time to update the methodology underpinning how we value - and ultimately price - drugs.
read full article ›